PMID- 8529469
OWN - NLM
STAT- MEDLINE
DCOM- 19960129
LR  - 20141120
IS  - 0196-4763 (Print)
IS  - 0196-4763 (Linking)
VI  - 21
IP  - 1
DP  - 1995 Sep 1
TI  - Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and 
      metastatic bladder cancer.
PG  - 40-6
AB  - To study the relationship of tumor genomic heterogeneity with bladder cancer 
      phenotype and p53 gene alterations, 138 primary bladder tumors were examined by 
      dual labeling fluorescence in situ hybridization (FISH) using probes for 
      chromosome 17 centromere (p17H8) and p53 (17p13.1). The number of different 
      aneusomic populations > 5% (and monosomic populations > 20%) of cells served as a 
      marker for heterogeneity. Nuclear p53 overexpression and Ki67 labeling index 
      (Ki67 LI) were determined by immunohistochemistry. The number of aneusomic 
      populations was 0 in 53 tumors, 1 in 18, 2 in 47, 3 in 9, and > 3 in 11 tumors. 
      Presence of aneusomy was associated with tumor grade and stage (P < 0.0001 each). 
      Ki67 LI was low in disomic tumors (11.0 +/- 7.7), higher in tumors with 1-3 
      aneusomic populations (17.4 +/- 11.3), and highest in tumors with > 3 aneusomic 
      populations (25.8 +/- 10.9; P = 0.02 for > 3 vs. 1-3 populations). Aneusomy and 
      heterogeneity were associated with p53 alterations. Aneusomy was seen in 35% of 
      tumors with neither p53 expression nor p53 deletion but in 97% of tumors with 
      both p53 deletion and expression. Nine of 11 tumors with > 3 aneusomic 
      populations exhibited both p53 deletion and overexpression. To study genomic 
      heterogeneity in tumor progression, two recurrences and three metastases of a 
      tumor with known erbB-2 amplification were examined for centromere 17 and erbB-2 
      copy number. A considerable heterogeneity in centromere 17 and erbB-2 gene copy 
      number was found in both recurrences and metastases, indicating a marked genomic 
      instability in these metastatic cells.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Sauter, G
AU  - Sauter G
AD  - Institute for Pathology, University of Basel, Switzerland.
FAU - Moch, H
AU  - Moch H
FAU - Gasser, T C
AU  - Gasser TC
FAU - Mihatsch, M J
AU  - Mihatsch MJ
FAU - Waldman, F M
AU  - Waldman FM
LA  - eng
GR  - CA47537/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cytometry
JT  - Cytometry
JID - 8102328
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Carcinoma, Transitional Cell/*genetics/*secondary
MH  - Cell Division/genetics
MH  - Chromosomes, Human, Pair 17/*genetics
MH  - Fluorescent Dyes
MH  - Gene Deletion
MH  - Gene Dosage
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - *Population
MH  - Receptor, ErbB-2/*genetics
MH  - Recurrence
MH  - Tumor Suppressor Protein p53/genetics
MH  - Urinary Bladder Neoplasms/*genetics/pathology/*secondary
EDAT- 1995/09/01 00:00
MHDA- 1995/09/01 00:01
CRDT- 1995/09/01 00:00
PHST- 1995/09/01 00:00 [pubmed]
PHST- 1995/09/01 00:01 [medline]
PHST- 1995/09/01 00:00 [entrez]
AID - 10.1002/cyto.990210109 [doi]
PST - ppublish
SO  - Cytometry. 1995 Sep 1;21(1):40-6. doi: 10.1002/cyto.990210109.